SEC Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Brilliant Acquisition Corporation, a special purpose acquisition company, on September 19, 2023, regarding events occurring on September 18, 2023. The filing concerns Brilliant’s proposed business combination with Nukkleus, Inc. The request metadata identifies T3 Defense Inc., but that entity is not the registrant named in the filing.
Key Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity balances, or other operating financial metrics.
The proposed transaction remains subject to, among other conditions, maintaining a minimum trust account amount after potential redemptions by Brilliant’s public shareholders.
Material Changes Versus the Prior Comparable Period
- On September 18, 2023, Nasdaq’s Hearings Panel granted Brilliant continued listing on The Nasdaq Capital Market through December 23, 2023, subject to specified conditions.
- Previously, Nasdaq had cited Brilliant’s failure to complete a business combination within the period required by Nasdaq IM-5101-2 and its failure to maintain minimum market value of listed securities of $35 million as potential delisting grounds.
- The Panel hearing occurred on August 31, 2023, following Brilliant’s timely request for a hearing.
Guidance, Outlook, Risks, and Unusual Items
- By November 27, 2023, Brilliant must update the Panel on the status of shareholder votes at both Brilliant and Nukkleus regarding the proposed transaction.
- The business combination must be completed by December 23, 2023, or Brilliant may lose its continued Nasdaq listing status.
- Completion remains subject to shareholder approvals, satisfaction of the minimum post-redemption trust account condition, applicable governmental and regulatory approvals, and other transaction conditions.
- Risks include failure to complete the transaction on time or at all, failure to obtain any required deadline extension, redemption levels, potential legal proceedings, disruption to Nukkleus’s business, employee-retention difficulties, securities-price volatility, regulatory changes, and inability to implement post-closing business plans.
- The filing states that the proposed transaction remains subject to SEC-filed proxy statement/prospectus materials and that investors should review the Form S-4 and related documents before voting or investing.
Important Facts for Investors to Verify
- Whether Brilliant and Nukkleus shareholders approve the proposed business combination.
- Whether the minimum trust account condition remains satisfied after redemptions.
- Whether the transaction closes by December 23, 2023, and whether any extension is obtained if needed.
- Whether Brilliant continues to satisfy Nasdaq listing requirements, including the $35 million minimum market value requirement.
- The final terms, ownership structure, dilution effects, and financial condition disclosed in the definitive proxy statement/prospectus.